Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/101864
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H- indol-3-yl)-ethyl]-Amide as a neuroprotectant for Alzheimers Disease by Hybridization of Curcumin and Melatonin |
Autor: | Chojnacki, J.E.; Liu, K.; Yan, X.; Toldo, S.; Selden, T.; Estrada, Martín CSIC ORCID CVN; Rodríguez-Franco, María Isabel CSIC ORCID ; Halquist, M.S.; Ye, D.; Zhang, S. | Fecha de publicación: | 2014 | Editor: | American Chemical Society | Citación: | ACS Chemical Neuroscience 5: 690- 699 (2014) | Resumen: | In our effort to develop effective neuroprotectants as potential treatments for Alzheimer>s disease (AD), hybrid compounds of curcumin and melatonin, two natural products that have been extensively studied in various AD models, were designed, synthesized, and biologically characterized. A lead hybrid compound (7) was discovered to show significant neuroprotection with nanomolar potency (EC50 = 27.60 ± 9.4 nM) in MC65 cells, a cellular AD model. Multiple in vitro assay results established that 7 exhibited moderate inhibitory effects on the production of amyloid-β oligomers (AβOs) in MC65 cells, but not on the aggregation of Aβ species. It also exhibited significant antioxidative properties. Further mechanistic studies demonstrated that 7>s antioxidant effects correlate well with its neuroprotective potency for MC65 cells, and these effects might be due to its interference with the interactions of AβOs within the mitochondria of MC65 cells. Furthermore, 7 was confirmed to cross the blood-brain barrier (BBB) and deliver a sufficient amount to brain tissue after oral administration. Collectively, these results strongly support the hybridization approach as an efficient strategy to help identify novel scaffolds with a desired pharmacology, and strongly encourage further optimization of 7 to develop more potent neuroprotectants for AD. | URI: | http://hdl.handle.net/10261/101864 | DOI: | 10.1021/cn500081s | Identificadores: | doi: 10.1021/cn500081s issn: 1948-7193 e-issn: 1948-7193 |
Aparece en las colecciones: | (IQM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
22
checked on 17-abr-2024
SCOPUSTM
Citations
71
checked on 19-abr-2024
WEB OF SCIENCETM
Citations
68
checked on 23-feb-2024
Page view(s)
399
checked on 19-abr-2024
Download(s)
109
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.